Precision Health’s Stars Align as GE Healthcare Launches Powerful New Nuclear Medicine System

GE Healthcare

By Jean-Luc Procaccini, President & CEO, Molecular Imaging and Computed Tomography, GE Healthcare

This is an exciting day for GE Healthcare and our Nuclear Medicine community as we proudly showcase StarGuide[1], GE Healthcare’s most advanced SPECT/CT system, at #RSNA21.

Just as stars have served as a reliable guide to adventurers for millennia, GE Healthcare’s new StarGuide SPECT/CT is designed to usher in a new age of discovery for research-focused clinicians.

Similar to using the North Star for direction, StarGuide’s shape adaptive gantry – made up of a dozen detectors – can help guide clinicians by narrowing the imaging field of view and focusing on the precise area of the patient that needs to be studied. Powered by our unique Optical Scout technology, StarGuide’s 12 slim Cadmium Zinc Telluride (CZT) Digital Focus Detectors orbit the body as closely as possible, and from all necessary angles, to scan the target area — and not the air surrounding the patient. The result is improved SPECT sensitivity and resolution,[2] which in turn helps clinicians pinpoint the size, shape, and position of lesions with exceptional accuracy. Paired with innovative reconstruction, the resulting images provide outstanding quantification for the diagnosis and staging of disease and monitoring of treatment.

StarGuide’s shape adaptive gantry and CZT detector technology also empowers clinicians to simultaneously image multiple tracers in a single scan, helping to reduce the need for multiple patient visits and sedations. It also supports the quality imaging of tracers used in Theranostics – including the Lutetium-177 (177Lu) tracer used for neuroendocrine and prostate cancers[1].

Altogether, StarGuide is designed to provide clinicians with the data they need to make personalized care decisions and treatment recommendations that are at the heart of precision health.

For greater insight into the potential impact of StarGuide, GE Healthcare spoke with Matthieu Bailly, Head of Nuclear Medicine, Physician and Gilles Le Rouzic, Medical Physicist at the Hospital of Orleans, France – the first global site for GE Healthcare’s StarGuide SPECT/CT system as well as Erez Levy, General Manager of Nuclear Medicine at GE Healthcare.

Q: Dr. Bailly, your institution was the first to use the StarGuide system. What benefits does it offer your department?

Bailly: StarGuide represents a breakthrough in the world of SPECT.

Thanks to the versatility of StarGuide’s shape adaptive gantry, we can narrow our field of view to focus on specific parts of the anatomy – such as the spine, heart or brain – to generate images with impressive detail not easily attained on conventional SPECT/CT systems. Using this technology, we are already redefining how we explore bone and cardiac assessments – and the ability to scan multiple isotopes at once is affording us opportunities to perform simultaneous imaging in a single session.

Q: In your opinion, which technical aspects of StarGuide are most innovative?

Le Rouzic: StarGuide allows us to acquire the patient’s data in the best conditions. The pixelated CZT modules combined with registered Dual-Channel tungsten collimation contribute to improved resolution and sensitivity compared to conventional SPECT/CT3. Every test we’ve conducted thus far shows better results than a standard NaI camera. All in all, the shape adaptive gantry of this new device is innovative by its very nature.

Q: From a clinical perspective, what opportunities are made possible by StarGuide?

Levy: Theranostics is a growing focus area in Nuclear Medicine, with many efforts being made to combine the delivery of therapy to patients with diagnosis to monitor disease. The opportunity to image 177Lu on StarGuide and evaluate a patient’s treatment response for neuroendocrine and prostate cancer marks an important step forward in helping to advance Theranostics and continue to improve patient care.3

While there is still much work to be done in the field of Theranostics and Precision Health, StarGuide offers clinicians unique opportunities to make personalized care decisions and treatment response assessments that are at the heart of Theranostics. GE Healthcare is uniquely positioned to advance these efforts as the only partner with solutions spanning from pharmaceutical diagnostics, cyclotrons, chemistry synthesis, PET/CT, PET/MR, nuclear medicine, advanced digital solutions and pharma partnerships to cover the breadth of steps from discovery to diagnosis to treatment.

For more information on GE Healthcare’s StarGuide system, visit

[1] StarGuide is FDA 510(k) cleared and CE marked. Available for sale in the US and EU countries. Not available for sale in all regions.

[2] StarGuide improves SPECT resolution with scatter, planar sensitivity, and SPECT sensitivity compared to NM/CT 870 DR using LEHR/LEHRS collimators and NM/CT 870 CZT using WEHR collimator. StarGuide SPECT reconstruction with scatter used the system’s factory NEMA NU 1-2018 resolution protocol which uses the same method (BSREM with Clarity 3D) as its clinical bone protocol. NM/CT 870 DR and NM/CT 870 CZT SPECT reconstruction used Evolution for Bone (OSEM). StarGuide’s planar sensitivity was measured for each of its 12 detectors and adapted from NEMA NU 1-2018.

[3] Radiopharmaceuticals may not be approved by ministers of health in all regions. 177Lu-PSMA is currently not an FDA approved tracer.